xianghua qi

Prof. Dr. xianghua qi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Medical Science Monitor
Verified
Journal Article
Open access
XKXinru Kong
Xinru Kong
YYYan Yao
Yan Yao
CWCuiying Wang
Cuiying Wang
YWYuangeng Wang
Yuangeng Wang
JTJing Teng
Jing Teng
XQxianghua qi
xianghua qi
Depression is a common disease worldwide, with about 280 million people having depression. The unique facial features of depression provide a basis for automatic recognition of depression with deep convolutional neural networks. In this study, we developed a depression recognition method based on facial images and a deep convolutional neural network. Based on 2-dimensional images, this method quantified the binary classification problem and distinguished patients with depression from healthy participants. Network training consisted of 2 steps: (1) 1020 pictures of depressed patients and 1100 pictures of healthy participants were used and divided into a training set, test set, and validation set at the ratio of 7: 2: 1; and (2) fully connected convolutional neural network (FCN), visual geometry group 11 (VGG11), visual geometry group 19 (VGG19), deep residual network 50 (ResNet50), and Inception version 3 convolutional neural network models were trained. The FCN model achieved an accuracy of 98.23% and a precision of 98.11%. The Vgg11 model achieved an accuracy of 94.40% and a precision of 96.15%. The Vgg19 model achieved an accuracy of 97.35% and a precision of 98.13%. The ResNet50 model achieved an accuracy of 94.99% and a precision of 98.03%. The Inception version 3 model achieved an accuracy of 97.10% and a precision of 96.20%. The results show that deep convolution neural networks can support the rapid, accurate, and automatic identification of depression.

13 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XKXinru Kong
Xinru Kong
CWChuang Wang
Chuang Wang
QWQiaolan Wu
Qiaolan Wu
ZWZiyue Wang
Ziyue Wang
YHYu Han
Yu Han
XQxianghua qi
xianghua qi
We aimed to identify the molecular biomarkers of MDD disease progression to uncover potential mechanisms of major depressive disorder (MDD). In this study, three microarray data sets, GSE44593, GSE12654, and GSE54563, were cited from the Gene Expression Omnibus database for performance evaluation. To perform molecular functional enrichment analyses, differentially expressed genes (DEGs) were identified, and a protein–protein interaction network was configured using the Search Tool for the Retrieval of Interacting Genes/Proteins and Cytoscape. To assess multi-purpose functions and pathways, such as signal transduction, plasma membrane, protein binding, and cancer pathways, a total of 220 DEGs, including 143 upregulated and 77 downregulated genes, were selected. Additionally, six central genes were observed, including electron transport system variant transcription factor 6, FMS-related receptor tyrosine kinase 3, carnosine synthetase 1, solute carrier family 22 member 13, prostaglandin endoperoxide synthetase 2, and protein serine kinase H1, which had a significant impact on cell proliferation, extracellular exosome, protein binding, and hypoxia-inducible factor 1 signaling pathway. This study enhances our understanding of the molecular mechanism of the occurrence and progression of MDD and provides candidate targets for its diagnosis and treatment.

9 July 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LWLiuding Wang
Liuding Wang
ZXZhen-Min Xu
Zhen-Min Xu
XLXiao Liang
Xiao Liang
WQWen-Ran Qiu
Wen-Ran Qiu
SLShao-Jiao Liu
Shao-Jiao Liu
XLXing Liao
Xing Liao
Importance. Panax Notoginseng Saponins (PNS) are proven to have antiplatelet effects in patients with acute ischemic stroke (AIS). Objective. To assess the efficacy and safety of PNS on antiplatelet therapy in the treatment of AIS. Methods. We searched 7 literature databases and 2 clinical studies databases for randomized controlled studies (RCTs) evaluating PNS as an adjuvant therapy for AIS. Relevant studies were retrieved and screened, and data were extracted independently by two reviewers. The quality of the included studies was assessed using the Cochrane Risk Assessment Tool. Meta-analysis was carried out with the Rev Man 5.4 software. Results. Of 8267 records identified, 43 RCTs met our inclusion criteria (n = 4170 patients). Patients assigned to PNS with conventional treatments (CTs) had improved functional independence at 90 days compared with those assigned to CTs alone (RR = 1.87, 95% CI = 1.37, to 2.55, ). Patients who received PNS combined with CTs showed significantly high improvements in neurological function among individuals with AIS on the neurologic deficit score (NDS) (MDCSS = −5.71, 95% CI = −9.55 to −1.87, ; MDNIHSS = −3.94, 95% CI = −5.65 to −2.23, ). The results also showed PNS contributed to a betterment in activities of daily living (ADL) on the Barthel index (MDday10 BI = 4.86, 95% CI = 2.18, to 7.54, ; MDday 14 BI = 13.92, 95% CI = 11.46 to 16.38, ; MDday 28 BI = 7.16, 95% CI = 0.60, to 13.72, ). In addition, PNS, compared with CTs alone, could significantly improve overall response rate (ORR) (RRNIHSS = 1.20, 95% CI = 1.16, to 1.24, ; RRCSS = 1.15, 95% CI = 1.08, to 1.24, ), hemorheological parameters, maximum platelet aggregation rate (MPAR) (MD = −6.82, 95% CI = −9.62 to −4.02, ), platelet parameters (MDPLT = 4.85, 95% CI = 1.82 to 7.84, ; MDMPV = −0.79, 95% CI = −1.09 to −0.48, ), and serum CD62P (MD = −0.21, 95% CI = −0.29 to −0.13, ). The incidence of adverse reactions in PNS was lower than that in the control group (RR = 0.62, 95% CI = 0.39 to 0.97, ). Adverse reactions in the PNS were mild adverse reactions. Conclusion. PNS may be effective and safe in treating AIS on ameliorating neurological deficit, improving activities of daily living function, and enhancing antiplatelet effects. However, more high-quality evidence is needed before it can be recommended for routine antiplatelet therapy in patients with AIS.

25 April 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
NYNi Yang
Ni Yang
LSLiangyuan Shi
Liangyuan Shi
PXPengfei Xu
Pengfei Xu
FRFang Ren
Fang Ren
SLShimeng Lv
Shimeng Lv
XQxianghua qi
xianghua qi
Introduction: Insomnia, a common clinical disorder, significantly impacts the physical and mental well-being of patients. Currently, available hypnotic medications are unsatisfactory due to adverse reactions and dependency, necessitating the identification of new drug targets for the treatment of insomnia.Methods: In this study, we utilized 734 plasma proteins as genetic instruments obtained from genome-wide association studies to conduct a Mendelian randomization analysis, with insomnia as the outcome variable, to identify potential drug targets for insomnia. Additionally, we validated our results externally using other datasets. Sensitivity analyses entailed reverse Mendelian randomization analysis, Bayesian co-localization analysis, and phenotype scanning. Furthermore, we constructed a protein-protein interaction network to elucidate potential correlations between the identified proteins and existing targets.Results: Mendelian randomization analysis indicated that elevated levels of TGFBI (OR = 1.01; 95% CI, 1.01–1.02) and PAM ((OR = 1.01; 95% CI, 1.01–1.02) in plasma are associated with an increased risk of insomnia, with external validation supporting these findings. Moreover, there was no evidence of reverse causality for these two proteins. Co-localization analysis confirmed that PAM (coloc.abf-PPH4 = 0.823) shared the same variant with insomnia, further substantiating its potential role as a therapeutic target. There are interactive relationships between the potential proteins and existing targets of insomnia.Conclusion: Overall, our findings suggested that elevated plasma levels of TGFBI and PAM are connected with an increased risk of insomnia and might be promising therapeutic targets, particularly PAM. However, further exploration is necessary to fully understand the underlying mechanisms involved.

22 February 2023 in Medicine
Verified
Journal Article
Open access
YWYuangeng Wang
Yuangeng Wang
CLChunlin Li
Chunlin Li
XQxianghua qi
xianghua qi
Background: The COVID-19 epidemic has placed a lot of mental burdens on school students, causing anxiety. Clinically, it has been found that the Yuji point (LU10) can relieve anxiety by regulating Qi. Methods: Thirty-six volunteers with anxiety disorders were divided into 3 groups, all of whom underwent 2 MRI examinations. The Yuji and nonacupoint groups received acupuncture between functional magnetic resonance imagings. We used the amplitude of low-frequency fluctuation to analyze regional brain activity, and seed-based functional connectivity (FC) to analyze changes in brain networks. Results: After acupuncture, the LU10 was able to activate the frontal lobe, medial frontal gyrus, anterior cingulate gyrus, temporal lobe, hippocampus, etc in the left brain compared to the control group. The frontal lobe, medial frontal gyrus, cingulate gyrus, and anterior cingulate gyrus in the left brain were activated compared to those in the nonacupoint group. Compared with the control group, LU10 showed increased FC in the right parietal lobe, right precuneus, left temporal lobe, left superior temporal gyrus, and with cingulate gyrus. FC was enhanced among the hippocampus with the left temporal lobe and the superior temporal gyrus and reduced in the right lingual gyrus and right occipital lobe. Conclusion: Acupuncture at LU10s can regulate anxiety by upregulating or downregulating the relevant brain regions and networks. LU10s can be used to treat not only lung disorders but also related mental disorders.

24 November 2023 in Medicine
Verified
Journal Article
Open access
ZWZiyue Mm Wang
Ziyue Mm Wang
HYHao Mm Yang
Hao Mm Yang
YHYu Mm Han
Yu Mm Han
JTJing Teng
Jing Teng
XKXinru Kong
Xinru Kong
XQxianghua qi
xianghua qi
This study aims to identify common molecular biomarkers between amyotrophic lateral sclerosis (ALS) and depression using bioinformatics methods, in order to provide potential targets and new ideas and methods for the diagnosis and treatment of these diseases. Microarray datasets GSE139384, GSE35978 and GSE87610 were obtained from the Gene Expression Omnibus (GEO) database, and differentially expressed genes (DEGs) between ALS and depression were identified. After screening for overlapping DEGs, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Furthermore, a protein-protein interaction (PPI) network was constructed using the STRING database and Cytoscape software, and hub genes were identified. Finally, a network between miRNAs and hub genes was constructed using the NetworkAnalyst tool, and possible key miRNAs were predicted. A total of 357 genes have been identified as common DEGs between ALS and depression. GO and KEGG enrichment analyses of the 357 DEGs showed that they were mainly involved in cytoplasmic translation. Further analysis of the PPI network using Cytoscape and MCODE plugins identified 6 hub genes, including mitochondrial ribosomal protein S12 (MRPS12), poly(rC) binding protein 1 (PARP1), SNRNP200, PCBP1, small G protein signaling modulator 1 (SGSM1), and DNA methyltransferase 1 (DNMT1). Five possible target miRNAs, including miR-221-5p, miR-21-5p, miR-100-5p, miR-30b-5p, and miR-615-3p, were predicted by constructing a miRNA-gene network. This study used bioinformatics techniques to explore the potential association between ALS and depression, and identified potential biomarkers. These biomarkers may provide new ideas and methods for the early diagnosis, treatment, and monitoring of ALS and depression.